FSN 2021-05-A & FSN 2021-06-A
As of October 2023, Philips Respironics has started repair activities of Trilogy 100/200 devices through Philips-approved repair centers in several countries. Please reach out to your Philips Respironics Account Manager for any additional questions.
Customers continue to have the choice between the repair of their devices, device buyback in the form of a sales credit, Trilogy Evo upgrades, and a Trilogy Evo loaner program. Our goal is to partner with customers to complete remediation as quickly as possible to address patients on affected Trilogy 100/200 devices.
Below is an update on the status of our repair and replacement program for impacted CPAP, BiPAP and mechanical ventilator devices as of October 31, 2024. In addition to the number of replacement devices delivered, we also provide an overview of the number of devices that will be financially compensated and the number of devices that can no longer be traced by home care providers.
1. A number of older System One sleep apnea devices are no longer manufactured and sold by Philips. In many cases, these devices are older than five years. In consultation with the home care providers, Philips has agreed on a solution for these patients. For part of the used devices, home care providers receive alternative or repaired devices. In addition, Philips offers financial compensation for some of these System One devices so that home care providers can purchase another device for the patient. 2. The home care providers have registered a number of devices that are no longer in use or can no longer be traced. The home care providers have made efforts to trace all devices and patients. We assume that devices that are no longer traceable are no longer in use.
You are about to visit a Philips global content page
Continue06 October 2023
27 September 2023
Philips Respironics completed the analyses for System One and DreamStation Go sleep therapy devices indicating that the volatile organic compounds (VOCs) and the particulate matter (PM) emissions related to foam degradation are within the appliable safety limits. Additional visual assessments have been performed and confirm the low prevalence of significant foam degradation.
A conversation with David Ferguson, Business Leader, Sleep and Respiratory Care David Ferguson, Business Leader, Sleep & Respiratory Care, joined Philips in March 2021. Since then, he has led the organization through the voluntary field safety notice of certain CPAP, BiPAP and Mechanical Ventilator devices. With the comprehensive test and research program for affected CPAP/BiPAP sleep therapy devices1 now complete, we asked him about what’s changed since the start of the field safety notice, what the test results mean for patients, and what to expect from Philips Respironics in the future.
1. First-generation DreamStation, System One and DreamStation Go devices
May 2023 - update on completed testing for home sleep therapy devices shows no appreciable harm to patients The tests, conducted together with five independent, certified testing laboratories and assessed by third-party qualified experts and Philips Respironics, as well as an external panel of experts, have now been completed and risk assessments evaluated for all home sleep therapy devices.
December 21, 2022 - Update on completed testing for first-generation DreamStation devices Based on the extensive testing and analysis that we have done over the past 18 months – working with five independent certified laboratories, as well as third party experts and physicians - we now have a complete set of results** for the first-generation DreamStation devices.
** Philips Respironics has provided the data and analyses to the FDA and other competent authorities. The FDA is still considering the data and analyses that Philips Respironics has provided and may reach different conclusions. Healthcare providers, patients, and other stakeholders should use the complete update, including information on the limitations of the testing, for any informed decision making and should not solely rely on the overview presented here. Philips Respironics’ guidance for healthcare providers and patients remains unchanged. Philips Respironics will continue with the remediation program.
November 23, 2022 - Philips provides an update related to Trilogy 100/200 repairs These problems do not affect any of the CPAP or BiPAP sleep apnea devices that have been remediated.
Philips Respironics has detected two problems with corrected Trilogy 100/200 ventilators following a limited number of complaints from the US and Japan.
July 25, 2022 - Summary of a systematic literature review of Positive Airway Pressure device use and cancer risk
Philips Respironics engaged external scientific experts to perform an independent systematic literature review of epidemiological studies to evaluate whether use of Continuous or Bilevel Positive Airway Pressure (PAP) devices increases the risk of cancer in obstructive sleep apnea (OSA) patients.
Based on 13 epidemiological studies identified from the systematic literature review, no association has been established between use of PAP devices, including Philips Respironics PAP devices, and risk of cancer in patients with OSA. Two rigorous independent studies showed no statistical difference in cancer risk between OSA patients who used Philips Respironics PAP devices versus other brands of PAP devices. Eleven other epidemiological studies provided little additional insight into this question, but their results generally suggested no excess risk of cancer associated with PAP use for OSA.
June 28, 2022 - Philips provides update on Philips Respironics’ PE-PUR sound abatement foam test and research program.
May 24, 2022 - An analysis was published online in the European Respiratory Journal that concluded that sustained and adherent CPAP therapy of OSA using Philips Respironics devices, compared with other manufacturers’ devices, was not associated with an increased risk of cancer after a median follow-up time of 7.2 years.
The analysis and conclusion were based on data from a large multicenter cohort study involving 4,447 OSA patients on CPAP devices between 2007 and 2018, including 1,648 Philips Respironics CPAP users. Philips Respironics was not involved in the study or the analysis.
Dec 15, 2021 - A completely independent Canadian study was published in the American Journal of Respiratory and Critical Care Medicine.
This study did not show a higher risk in patients with CPAP compared to patients using a device from another manufacturer.
August 7, 2023
Click here to learn moreJune 13, 2023
Click here to learn moreFebruary 16, 2023
Click here to learn moreSeptember 3, 2021
Click here to learn moreYou are about to visit a Philips global content page
Continue